TJ-CP3B / TJ Biopharma - LARVOL DELTA

TJ-CP3B, a Novel Tri-specific T Cell Engager with 4-1BB Conditional Activation to Target CDCP1 for Solid Tumors (SITC 2025) - "The novel addition of 4-1BB conditional activation, as compared to conventional CD3-TCEs, provides a unique synergism that enables adequate intra-tumor T cell activation even in the condition where there is very limited T cell infiltration. TJ-CP3B is currently in development as a promising drug candidate for cancer immunotherapy targeting CDCP1-positive malignancies."

IO biomarker • Trispecific • Oncology • Solid Tumor • CDCP1